| Description: | This is a double-blinded, randomized, placebo-controlled Phase 3 trial of ProstAtak™(AdV-tk + valacyclovir) in combination with standard external beam radiation therapy with or without androgen deprivation therapy (ADT) for intermediate-high risk localized prostate cancer. ProstAtak™ is an investigational product that kills tumor cells and elicits an anti-tumor vaccine effect. The hypothesis is that this combination therapy can lead to improvement in the clinical outcome for patients with newly diagnosed prostate cancer. Patients will be randomized to the ProstAtak™ or control arm at a 2:1 ratio. |
|---|
{"serverDuration": 78, "requestCorrelationId": "79faae9c5ad0dde5"}